ZIVO Bioscience (ZIVO) 10-Q2021 Q1 Quarterly report

Filed: 17 May 21, 4:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Additionally, adequate, affirmed, aforementioned, aimed, Aquaculture, aquafeed, Arizona, Arrangement, assuming, bacterial, beneficially, beverage, boost, bovine, canine, cell, certificate, characterized, cholesterol, chondroprotective, compelled, compensatory, complex, compound, comprised, consummation, consumption, COREir, CorProminence, culture, cycle, dba, death, declared, Delaware, demand, departure, digestive, directly, Disability, disease, dried, drug, efficacy, evidence, expansion, facility, fatty, favor, favorable, FC, FCCA, fed, feed, fifteen, Florida, foregoing, foreseeable, fraction, Ft, Grekin, gut, hand, harvest, hatch, higher, holiday, human, India, ingestible, introduced, iron, lab, laboratory, lessee, lower, Marchiando, member, mill, mixed, modulating, Modulation, modulator, molecular, MPR, multiple, Myer, network, Nevada, NutriQuest, nutrition, nutritional, Occupancy, Outlook, partial, partially, Peru, pocket, policy, portfolio, poultry, practically, produced, protein, rapidly, ratio, receipt, Recovery, refine, remining, resign, resigned, reverse, rheumatoid, seek, skin, source, space, stage, strain, strategic, Subscription, suitability, suitable, Sustainable, sustained, system, thirteen, threatened, tied, treated, treatment, twenty, underwriting, underwritten, unfavorable, valuation, viable, view, virtue, Vitamin, vitro, vivo, waiver, warehouse, yielded, Zoologic

Removed: affecting, amounted, analyzer, assembling, authoritative, banking, bulk, centered, CFO, chemistry, Christopher, collaborating, communication, compliant, contracted, curtail, deduction, derive, device, difficulty, dry, effort, ending, face, FDA, fiscal, focused, healthy, heavily, inflammation, initially, largely, larger, licensed, listing, Maggiore, manner, medical, metabolic, milestone, move, negotiating, offshore, optimizing, oxidation, package, parallel, past, put, redemption, reflected, reliant, representing, run, scientific, shortage, submitted, subsidiary, synthetic, therapeutic, toll, trial, unamortized, validate

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ZIVO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(Subsections (a) and (b) of Section 1350,

Chapter 63 of Title 18, United States Code)

In connection with the Quarterly Report on Form 10-Q for the period ending March 31, 2021 of Zivo Bioscience, Inc. (the “Company”), Inc., a Nevada corporation (the “Company”), as filed with the Securities and Exchange Commission (the “Report”), I, Andrew Dahl, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date:	May 17, 2021

	/s/Andrew Dahl
	Andrew Dahl,
	Chief Executive Officer

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HEALTH ENHANCEMENT PRODUCTS, INC. AND WILL BE RETAINED BY HEALTH ENHANCEMENT PRODUCTS, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.